Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world comparison of THP versus TH + HER2-TKI regimens in HER2-positive advanced breast cancer
ChiCTR2500103653Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pertuzumab, trastuzumab, docetaxel, paclitaxel, pyrotinib and 2 more in breast cancer (2 arms), sponsored by Union Hospital. Primary endpoints: Progression-free survival and Incidence of adverse drug reactions and adverse events. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500103653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103653.